Brain Tumour Research publications

Selected publications

Full listing of Professor C Oliver Hanemann’s publications available from PubMed and via Orcid ID


Edge R, Mills R, Tennant A, Diggle PJ & Young CA (2019) 'Do pain, anxiety and depression influence quality of life for people with amyotrophic lateral sclerosis/motor neuron disease? A national study reconciling previous conflicting literature' Journal of Neurology 267, (3) pp 607-615. Read this article

Young CA, Ealing J, McDermott C, Williams T, Al-Chalabi A, Majeed T, Burke G, Pinto A, Dick D & Talbot K (2019) 'The relationships between symptoms, disability, perceived health and quality of life in amyotrophic lateral sclerosis/motor neuron disease' Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 20, (5-6) pp 317-327. Read this article

Shefner JM, Cudkowicz ME, Hardiman O, Cockroft BM, Lee JH, Malik FI, Meng L, Rudnicki SA, Wolff AA & Andrews JA (2019) 'A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis' Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 20, (7-8) pp 584-594. Read this article

Mills SJ, Radon MR, Baird RD, Hanemann CO, Keatley D, Lewis J, Pollock J, Sanghera P, Santarius T & Whitfield G (2019) 'Utilization of volumetric magnetic resonance imaging for baseline and surveillance imaging in Neuro-oncology' The British Journal of Radiology pp 20190059-20190059. Read this article

Halliday D, Emmanouil B, Vassallo G, Lascelles K, Nicholson J, Chandratre S, Anand G, Wasik M, Pretorius P & Evans DG (2019) 'Trends in phenotype in the English paediatric neurofibromatosis type 2 cohort stratified by genetic severity' Clinical Genetics: an international journal of genetics and molecular medicine 96, (2) pp 151-162. Read this article

Hanemann CO, Ammoun S, Evans G, Hilton DA, Streeter A & Hayward C (2019) 'Phase 0 trial investigating the intra-tumoural concentration and activity of Sorafenib in Neurofibromatosis type 2' Journal of Neurology, Neurosurgery and Psychiatry. Read this article

Suppiah S, Nassiri F, Bi WL, Dunn IF, Hanemann CO, Horbinski CM, Hashizume R, James CD, Mawrin C & Noushmehr H (2019) 'Molecular and translational advances in meningiomas' Neuro-Oncology 21, (Supplement_1) pp i4-i17. Read this article


Dunn J, Ferluga S, Sharma V, Futschik M, Hilton DA, Adams CL, Lasonder E & Hanemann CO (2018) 'Proteomic analysis discovers the differential expression of novel proteins and phosphoproteins in meningioma including NEK9, HK2 and SET and deregulation of RNA metabolism' EBioMedicine Read this article

Hanemann CO, Emmanouil B, Houston R, May A, Ramsden JD, Halliday D, Parry A & Mackeith S (2018) 'Progression of Hearing Loss in Neurofibromatosis Type 2 According to Genetic Severity' The Laryngoscope Read this article

Collord G, Tarpey P, Kurbatova N, Martincorena I, Moran S, Castro M, Nagy T, Bignell G, Maura F & Young MD (2018) 'An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures' Scientific Reports 8, (1) pp 13537-13537 Read this article

Milinis K, Tennant A, Mills RJ, Al-Chalabi A, Burke G, Dick DJ, Ealing J, Hanemann CO, Harrower T & McDermott CJ (2018) 'Development and validation of Spasticity Index-Amyotrophic Lateral Sclerosis' Acta Neurologica Scandinavica Read this article


Stepanova DS, Semenova G, Kuo YM, Andrews AJ, Ammoun S, Hanemann CO, Chernoff J (2017) ‘An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis’ Cancer Res 77, (18) 5026-5038. Read this article

Provenzano L, Ryan Y, Hilton DA, Lyons-Rimmer J, Dave F, Maze EA, Adams CL, Rigby-Jones R, Ammoun S, Hanemann CO (2017) ‘Cellular prion protein (PrPC) in the development of Merlin-deficient tumours’ Oncogene 36, (44) 6132-6142. Read this article

Mindos T, Dun XP, North K, Doddrell RD, Schulz A, Edwards P, Russell J, Gray B, Roberts SL, Shivane A, Mortimer G, Pirie M, Zhang N, Pan D, Morrison H, Parkinson DB (2017) ‘Merlin controls the repair capacity of Schwann cells after injury by regulating Hippo/YAP activity’ J Cell Biol. 216 (2) 495-510. Read this article

Oon CE, Bridges E, Sheldon H, Sainson RCA, Jubb A, Turley H, Leek R, Buffa F, Harris AL, Li JL (2017) ‘Role of Delta-like 4 in Jagged1-induced tumour angiogenesis and tumour growth’ Oncotarget 8, (25) 40115-40131. Read this article


Hanemann CO, Blakeley JO, Nunes FP, Robertson K, Stemmer-Rachamimov A, Mautner V, Kurtz A, Ferguson M, Widemann BC, Evans DG, Ferner R, Carroll SL, Korf B, Wolkenstein P, Knight P, Plotkin SR (2016) ‘Current status and recommendations for biomarkers and biobanking in neurofibromatosis’ Neurology 87, (7 Supplement 1), S40-S48. Read this article 

Zhou L, Lyons-Rimmer J, Ammoun S, Müller J, Lasonder E, Sharma V, Ercolano E, Hilton D, Taiwo I, Barczyk M, Hanemann CO (2016) ‘The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors’ Oncogene 35, (26) 3443-3453. Read this article

Schulz A, Büttner R, Hagel C, Baader SL, Kluwe L, Salamon J, Mautner VF, Mindos T, Parkinson DB, Gehlhausen JR, Clapp DW, Morrison H (2016) ‘The importance of nerve microenvironment for schwannoma development’ Acta Neuropathol. 2016 Aug;132(2):289-307. Read this article


McDermott CJ, Shaw PJ, Cooper CL, Dixon S, Baird WO, Bradburn MJ, Fitzgerald P, Maguire C, Williams T, Baudouin SV, Karat D, Talbot K, Stradling J, Maynard N, Turner M, Bianchi S, Ackroyd R, Bourke SC, Ealing J, Bentley A, Galloway S, Orrell RW, Wedzicha W, Elliot M, Hughes P, Hanemann CO (2015) ‘Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial’ Lancet Neurol 14, (9) 883-892. Read this article

McDermott CJ, Shaw PJ, Stavroulakis T, Walters SJ, Al-Chalabi A, Chandran S, Crawley F, Dick D, Donaghy C, Eames P, Fish M, Gent C, Gorrie G, Hamdalla H, Hanemann CO, Johnson M, Majeed T, Malaspina A, Morrison K, Orrell R, Pinto A, Radunovic A, Roberts M, Talbot K, Turner MR, Williams T, Young C (2015) ‘Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study’ Lancet Neurol 14, (9) 702-707. Read this article

Ammoun S, Schmid MC, Zhou L, Hilton DA, Barczyk M, Hanemann CO (2015) ‘The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours’ Mol Oncol 9, (1) 236-248. Read this article


Li W, Cooper J, Zhou L, Yang C, Erdjument-Bromage H, Zagzag D, Snuderl M, Ladanyi M, Hanemann CO, Zhou P, Karajannis MA, Giancotti FG (2014) ‘Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus’ Cancer Cell 26, (1) 48-60. Read this article

Ammoun S, Provenzano L, Zhou L, Barczyk M, Evans K, Hilton DA, Hafizi S, Hanemann CO (2014) ‘Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival’ Oncogene 33, (3) 336-346. Read this article


Plotkin SR, Blakeley JO, Dombi E, Fisher MJ, Hanemann CO, Walsh KS, Wolters PL, Widemann BC (2013) ‘Achieving consensus for clinical trials The REiNS International Collaboration’ Neurology 81, (21) S1-S5. Read this article

Schulz A, Baader SL, Niwa-Kawakita M, Jung MJ, Bauer R, Garcia C, Zoch A, Schacke S, Hagel C, Mautner VF, Hanemann CO, Dun XP, Parkinson DB, Weis J, Schröder JM, Gutmann DH, Giovannini M, Morrison H (2013) ‘Merlin isoform 2 in neurofibromatosis type 2-associated polyneuropathy’ Nature Neurosci 16, (4) 426-U86. Read this article

Doddrell RD, Dun XP, Shivane A, Feltri ML, Wrabetz L, Wegner M, Sock E, Hanemann CO, Parkinson DB (2013) ‘Loss of SOX10 function contributes to the phenotype of human Merlin-null schwannoma cells’ Brain 136, (Pt 2) 549-563. Read this article 


Sher I, Hanemann CO, Karplus PA, Bretscher A (2012) ‘The tumor suppressor merlin controls growth in its open state, and phosphorylation converts it to a less-active more-closed state’ Dev Cell 22, (4) 703-705. Read this article

Ammoun S, Schmid MC, Zhou L, Ristic N, Ercolano E, Hilton DA, Perks CM, Hanemann CO (2012) ‘Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival’ Oncogene 31, (13) 1710-1722. Read this article


Ammoun S, Schmid MC, Triner J, Manley P, Hanemann CO (2011) ‘Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2’ Neuro Oncol 13, (7) 759-766. Read this article

Ammoun S, Hanemann CO (2011) ‘Emerging therapeutic targets in schwannomas and other merlin-deficient tumors’ Nat Rev Neurol 7, (7) 392-9. Read this article


Ammoun S, Cunliffe CH, Allen JC, Chiriboga L, Giancotti FG, Zagzag D, Hanemann CO, Karajannis MA (2010) ‘ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma’ Neuro Oncol 8, (12) 834-43. Read this article

Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, Ishii R, Giovannini M, Hanemann CO, Long SB, Erdjument-Bromage H, Zhou P, Tempst P, Giancotti FG (2010) ‘Merlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4(DCAF1) in the Nucleus’ Cell 140, (4) 477-490. Read this article


Ammoun S, Flaiz C, Ristic N, Schuldt J, Hanemann CO (2008) ‘Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma’ Cancer Res 68, (13) 5236-5245. Read this article

Flaiz C, Utermark T, Parkinson DB, Poetsch A, Hanemann CO (2008) ‘Impaired intercellular adhesion and immature adherens junctions in merlin-deficient human primary schwannoma cells’ Glia 56, (5) 506-515. Read this article

Hanemann CO (2008) ‘Magic but treatable? Tumours due to loss of Merlin’ Brain 131, 606-615. Read this article

Hanemann CO, Diebold R, Kaufmann D (2007) ‘Role of NF2 Haploinsufficiency in NF2-associated Polyneuropathy’ Brain Pathol 17, (4) 371-376. Read this article